{"analyses":[{"ciLowerLimit":"0.9","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.6","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1390","paramType":"Odds Ratio (OR)","paramValue":"1.7","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.4","upperLimit":"93.7","value":"89.3"},{"groupId":"OG001","lowerLimit":"73.6","upperLimit":"89.2","value":"82.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"DCR by BICR (with or without Pembrolizumab) is defined as the number of participants who achieve a BOR of CR, PR, or SD lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)"}],"paramType":"NUMBER","populationDescription":"ITT Population: All randomized participants, even if a participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol. Participants were analyzed according to the treatment arm they were assigned to regardless of what actual treatment they received.","reportingStatus":"POSTED","timeFrame":"Baseline to Progressive Disease or Death from Any Cause Up to 31 Months","title":"Percentage of Participant With DCR by BICR (With or Without Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}